ANI Pharmaceuticals (ANIP) stock surged 6.25% in pre-market trading on Friday following the company's announcement of record first-quarter 2025 financial results and an upward revision of its full-year guidance. The pharmaceutical company's performance significantly exceeded analyst expectations, demonstrating strong momentum in its business operations.

For the first quarter of 2025, ANI Pharmaceuticals reported adjusted earnings per share (EPS) of $1.70, handily beating the FactSet consensus estimate of $1.38. The company's revenue for the quarter reached $197.1 million, substantially surpassing analyst projections of $180.7 million. This impressive top-line performance represents a notable increase from the $137.4 million reported in the same quarter last year.

Buoyed by its strong first-quarter performance, ANI Pharmaceuticals has raised its full-year 2025 guidance. The company now expects adjusted EPS in the range of $6.27 to $6.62, up from its previous forecast of $6.12 to $6.49. Additionally, ANI has increased its revenue outlook to between $768 million and $793 million, compared to the earlier projection of $756 million to $776 million. These revised figures surpass the current consensus estimates, which stand at $6.34 for EPS and $769.6 million for revenue, underlining the company's confidence in its growth trajectory for the remainder of the year.